Get started
Work

First-line fovinaciclib versus placebo combined with aromatase inhibitor for advanced breast cancer: A randomized, double-blind phase 3 study.

Year: 2026
Type: conference-abstract
DOI: 10.1200/jco.2026.44.16_suppl.1090
Authors: Peng Yuan, Binghe Xu, Yunjiang Liu, Wei Li, Huiping Li, Zhongsheng Tong, Jing Cheng, Mingjuan Zhang, Jinlu Shan, Jincai Zhong, Tienan Yi, Jian Liu, Huihui Li, Zhen Huang, Jinsheng Wu, Sijuan Ding, Liang Li, Yuhui Peng, Xiaoran Yang, FCN-437c-III201 Investigators
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Fourth Hospital of Hebei Medical University, First Bethune Hospital of Jilin University, Peking University Cancer Hospital, Shandong First Medical University, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Huazhong University of Science and Technology, Weihai Municipal Hospital, Guangxi Medical University, First Affiliated Hospital of GuangXi Medical University, Xiangyang Central Hospital, Fujian Provincial Cancer Hospital, Tumor Hospital of Guangxi Medical University, Hainan Medical University, Meizhou City People's Hospital
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7162490029
Cites:
Cited by:
Related to: